BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38244072)

  • 1. Analysis of the immunological markers BTLA, TIM-3, and PD-L1 at the invasion front and tumor center in clear cell renal cell carcinoma.
    Stühler V; Alemi B; Rausch S; Stenzl A; Schwab M; Schaeffeler E; Bedke J
    World J Urol; 2024 Jan; 42(1):53. PubMed ID: 38244072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
    Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
    Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer.
    Möller K; Fraune C; Blessin NC; Lennartz M; Kluth M; Hube-Magg C; Lindhorst L; Dahlem R; Fisch M; Eichenauer T; Riechardt S; Simon R; Sauter G; Büscheck F; Höppner W; Matthies C; Doh O; Krech T; Marx AH; Zecha H; Rink M; Steurer S; Clauditz TS
    Int Urol Nephrol; 2021 Dec; 53(12):2493-2503. PubMed ID: 33797012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and prognostic significance of PD-L1, TIM-3 and B7-H3 expression in endometrial serous carcinoma.
    Chen H; Molberg K; Carrick K; Niu S; Rivera Colon G; Gwin K; Lewis C; Zheng W; Castrillon DH; Lucas E
    Mod Pathol; 2022 Dec; 35(12):1955-1965. PubMed ID: 35804040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological and prognostic significance of PD-L1 and TIM-3 expression in medullary thyroid carcinoma: a retrospective immunohistochemistry study.
    Wusiman D; Guo L; Li L; Zhang X; Zhao X; An Z; Huang Z; Zhang Y; Li Z; Ying J; Wei M; Li W; An C
    J Endocrinol Invest; 2024 Jan; 47(1):91-100. PubMed ID: 37464189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia.
    Curley J; Conaway MR; Chinn Z; Duska L; Stoler M; Mills AM
    Mod Pathol; 2020 Jun; 33(6):1182-1192. PubMed ID: 32139873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
    Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
    Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of PD-1, TIM-3, LAG-3 and BTLA in diffuse large B-cell lymphoma and its effect on prognosis].
    Liu XY; Yuan XL; Ma RJ; Xu H; Yang SW; Nie L; Zhang L; Hu AX; Li Z; Zhu ZM
    Zhonghua Yi Xue Za Zhi; 2020 Sep; 100(36):2846-2853. PubMed ID: 32988145
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer.
    Chevalier MF; Bohner P; Pieraerts C; Lhermitte B; Gourmaud J; Nobile A; Rotman S; Cesson V; Martin V; Legris AS; Dartiguenave F; Gharbi D; De Leval L; Speiser DE; Nardelli-Haefliger D; Jichlinski P; Derré L
    Eur Urol; 2017 Jun; 71(6):854-857. PubMed ID: 28277277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
    Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
    World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
    Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
    Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
    J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma.
    Eckel-Passow JE; Ho TH; Serie DJ; Cheville JC; Houston Thompson R; Costello BA; Dong H; Kwon ED; Leibovich BC; Parker AS
    Cancer Med; 2020 Feb; 9(3):1152-1160. PubMed ID: 31829518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.
    Zhang L; Wang J; Wei F; Wang K; Sun Q; Yang F; Jin H; Zheng Y; Zhao H; Wang L; Yu W; Zhang X; An Y; Yang L; Zhang X; Ren X
    Oncotarget; 2016 Jul; 7(28):43604-43615. PubMed ID: 27283895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological implications of the expression of vascular endothelial growth factor and programmed death ligand 1 in clear-cell renal cell carcinoma.
    Lee KS; Yun S; Lee K; Moon S; Choe G
    Hum Pathol; 2020 May; 99():88-97. PubMed ID: 32246989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients.
    Wang H; Mao L; Zhang T; Zhang L; Wu Y; Guo W; Hu J; Ju H; Ren G
    J Oral Pathol Med; 2019 Sep; 48(8):669-676. PubMed ID: 31132187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients.
    Wang Q; Zhang J; Tu H; Liang D; Chang DW; Ye Y; Wu X
    J Immunother Cancer; 2019 Nov; 7(1):334. PubMed ID: 31783776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 expression is an unfavourable prognostic indicator in Asian renal cell carcinomas.
    Yeong J; Zhao Z; Lim JCT; Li H; Thike AA; Koh VCY; Teh BT; Kanesvaran R; Toh CK; Tan PH; Khor LY
    J Clin Pathol; 2020 Aug; 73(8):463-469. PubMed ID: 31980560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry.
    Kim SH; Park WS; Park EY; Park B; Joo J; Joung JY; Seo HK; Lee KH; Chung J
    PLoS One; 2017; 12(6):e0179610. PubMed ID: 28654655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1.
    Zhang C; Duan Y; Xia M; Dong Y; Chen Y; Zheng L; Chai S; Zhang Q; Wei Z; Liu N; Wang J; Sun C; Tang Z; Cheng X; Wu J; Wang G; Zheng F; Laurence A; Li B; Yang XP
    Clin Cancer Res; 2019 Nov; 25(22):6827-6838. PubMed ID: 31383732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.